Table of Contents
Trial overview
The source data includes one completed clinical trial of Atomoxetine Hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder (ADHD).[1] This study was an interventional trial, which means the researchers gave study treatment and then measured outcomes over time.[1]
The trial compared long-term treatment effects in patients with ADHD who could not use stimulant medicines well because the stimulants were not suitable, not tolerated, or not effective.[1] The study also compared Atomoxetine Hydrochloride with TAK-503, but the provided source data only gives detailed trial information for the Atomoxetine Hydrochloride arm as part of the comparison.[1]
Who was studied
The trial included children and adolescents aged 6 to 17 years.[1] All participants had ADHD.[1] The study was aimed at a group of patients with more limited treatment options, because stimulants were not suitable, not tolerated, or not effective for them.[1]
This matters because clinical trials often focus on a specific age group and a specific type of patient, so the results apply best to people who match those study features.[1]
What was measured
The main safety endpoint was the change from baseline in the CANTAB RTI task.[1] Baseline means the starting point before treatment effects were measured.[1] The CANTAB RTI task is a computer-based test used to measure reaction time, which gives information about psychomotor speed and attention.[1]
The brief summary also states that the study evaluated long-term safety and compared Atomoxetine Hydrochloride after 12 months of once-daily treatment on psychomotor speed and attention.[1] The effect on cognition, which means thinking ability, was assessed and interpreted using the full set of study data.[1]
Study design and phase
This was a Phase 3 study.[1] Phase 3 trials are usually larger studies that help researchers learn more about safety and how well a treatment performs in the target population.[1]
The study was also described as a long-term evaluation, with results assessed after 12 months of once-daily treatment.[1] The enrollment was 287 participants, which gives an idea of the study size.[1]
Results in the source data
The source data provided here does not include final outcome numbers or detailed efficacy results for Atomoxetine Hydrochloride.[1] It does show that the trial was completed, so the study was finished and the planned assessments were carried out.[1]
Because the available information is limited to one trial record, this article focuses on the study question, patient group, phase, and main endpoint rather than on comparative results.[1]
